

Brief Summary of the CLS Year

In Europe our TRANBERG® systems have been demonstrated during hands on training sessions at ECIO in Vienna that took place in April and Imperial Prostate Masterclass in London in September. The sessions were all fully booked and there were a lot of interested questions from the audience.



At the iMRI meeting in Leipzig in October clinical data from University Health Network, Toronto, was presented sharing 24-month data from the study using CLS TRANBERG® products.

The investigators concluded that targeted focal therapy of intermediate-risk prostate cancer performed under MRgFLA is safe with encouraging 2-year oncological and functional outcomes. [Abstract link](#).

In the US our subsidiary CLS Americas introduced our office-based system for MR/US fusion-guided high precision, focal laser ablation of soft tissue, such as prostate cancer tumors, during the AUA 2022 Conference that was held in May in New Orleans.

During the Focal 2022 Conference in September Dr. Fernando J. Bianco, shared his experiences from his ongoing 20-patient, Phase I clinical study using the TRANBERG and Focalyx systems titled, “*Targeted MRI/US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer*”, during a lunch symposium. His lecture is available here [Presentation by Dr Fernando J. Bianco, Focal 2022](#).

FDA 510(k) Clearance for our MR guided laser ablation system for neurosurgery was received in September. The clearance marks a breakthrough in the field of neurosurgery and for minimally invasive treatments of brain lesions that will now be performed more efficiently and safely. The system is now being commercialized by our global distributor ClearPoint Neuro Inc.

[In an interview Joseph Burnett](#), President & CEO of Clearpoint Neuro Inc., he explains the benefits and potential of the combined system and how one team of physicians will be able to perform the laser ablation procedure inside the MRI scanner.

In December the first patient was treated in Europe, in a study at Skåne University Hospital on patients suffering from glioblastoma.



News from the CLS Team

During the year we have also welcomed some new employees, who already contribute to the team with their in-depth knowledge and experience in their respective areas of expertise:

- **Mark Halberstadt**, *Clinical Application Specialist*, with special focus on our MRI-guided therapy systems.
- **Joel Hix**, *Clinical Application Specialist*, with special focus on US-Fusion guided therapy of prostate cancer.
- **Jonas Larsson**, *QA/RA Engineer*, with focus on establishment and maintenance of the Quality System (OneCLS).
- **Rolf Bornschein**, *CFO*, with responsibility for finance, IR and HR. Rolf is part of our executive management team.



Finally, in November our **CTO Cristina Pantaleone** was rewarded Technician of the Year by the Chamber of Commerce and Industry of Southern Sweden!

Wishing you all a very happy holiday season. We look forward to a tremendous 2023!

